Assembly Biosciences (ASMB) Stock Forecast, Price Target & Predictions
ASMB Stock Forecast
Assembly Biosciences stock forecast is as follows: an average price target of $35.50 (represents a 133.40% upside from ASMB’s last price of $15.21) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
ASMB Price Target
The average price target for Assembly Biosciences (ASMB) is $35.50 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $36.00 to $35.00. This represents a potential 133.40% upside from ASMB's last price of $15.21.
ASMB Analyst Ratings
According to 2 Wall Street analysts, Assembly Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for ASMB stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 1 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Assembly Biosciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 24, 2024 | Salim Syed | Mizuho Securities | $36.00 | $16.26 | 121.40% | 136.69% |
| Sep 20, 2024 | Dennis Ding | Jefferies | $35.00 | $18.50 | 89.19% | 130.11% |
The latest Assembly Biosciences stock forecast, released on Sep 24, 2024 by Salim Syed from Mizuho Securities, set a price target of $36.00, which represents a 121.40% increase from the stock price at the time of the forecast ($16.26), and a 136.69% increase from ASMB last price ($15.21).
Assembly Biosciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 2 |
| Avg Price Target | - | $35.50 | $35.50 |
| Last Closing Price | $15.21 | $15.21 | $15.21 |
| Upside/Downside | -100.00% | 133.40% | 133.40% |
In the current month, the average price target of Assembly Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Assembly Biosciences's last price of $15.21. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 24, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
| Sep 20, 2024 | Jefferies | Buy | Upgrade |
Assembly Biosciences's last stock rating was published by H.C. Wainwright on Sep 24, 2024. The company gave ASMB a "Neutral" rating, the same as its previous rate.
Assembly Biosciences Financial Forecast
Assembly Biosciences Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.04M | $34.61M | $39.38M | $4.08M | $4.77M | $4.23M | $3.08M | $3.88M | $3.57M | $684.37K |
| Avg Forecast | $3.80M | $4.06M | $4.00M | $8.50M | $8.60M | $8.40M | $8.15M | $7.95M | $5.20M | $5.77M | $6.00M | $1.56M | $1.63M | $2.51M | $3.97M | $6.44M | $30.54M | $3.82M | $3.73M | $3.44M | $3.65M | $3.21M | $3.39M | $25.18K |
| High Forecast | $3.97M | $4.24M | $4.18M | $8.89M | $9.00M | $8.79M | $8.53M | $8.48M | $5.68M | $6.03M | $6.28M | $1.56M | $1.63M | $2.51M | $3.97M | $6.44M | $30.54M | $3.82M | $3.73M | $3.44M | $3.65M | $3.21M | $4.07M | $30.22K |
| Low Forecast | $3.62M | $3.87M | $3.82M | $8.11M | $8.20M | $8.01M | $7.77M | $7.42M | $4.71M | $5.50M | $5.72M | $1.56M | $1.63M | $2.51M | $3.97M | $6.44M | $30.54M | $3.82M | $3.73M | $3.44M | $3.65M | $3.21M | $2.71M | $20.15K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 7 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 10 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.26% | 5.38% | 1.29% | 1.07% | 1.28% | 1.23% | 0.84% | 1.21% | 1.05% | 27.17% |
Assembly Biosciences's average Quarter revenue forecast for Mar 21 based on 7 analysts is $2.51M, with a low forecast of $2.51M, and a high forecast of $2.51M. ASMB's average Quarter revenue forecast represents a 141.67% increase compared to the company's last Quarter revenue of $1.04M (Dec 20).
Assembly Biosciences EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 7 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 10 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | $-62.79M | $-23.48M | $-27.09M | $-39.10M | $-3.21M | $7.39M | $-26.54M | $-27.71M | $-24.89M | $-18.39M | $-26.92M | $-16.08M | $-13.90M |
| Avg Forecast | $-2.14M | $-2.29M | $-2.26M | $-4.79M | $-4.85M | $-4.74M | $-4.59M | $-4.48M | $-2.93M | $-3.25M | $-3.38M | $-878.73K | $-913.29K | $-30.59M | $-2.23M | $-3.62M | $-17.17M | $-32.50M | $-2.10M | $-1.94M | $-2.05M | $-26.67M | $-15.23M | $-312.72M |
| High Forecast | $-2.04M | $-2.18M | $-2.15M | $-4.57M | $-4.62M | $-4.52M | $-4.38M | $-4.18M | $-2.66M | $-3.10M | $-3.23M | $-878.73K | $-913.29K | $-24.47M | $-2.23M | $-3.62M | $-17.17M | $-26.00M | $-2.10M | $-1.94M | $-2.05M | $-21.33M | $-12.19M | $-250.18M |
| Low Forecast | $-2.24M | $-2.39M | $-2.36M | $-5.01M | $-5.07M | $-4.95M | $-4.81M | $-4.78M | $-3.20M | $-3.40M | $-3.54M | $-878.73K | $-913.29K | $-36.71M | $-2.23M | $-3.62M | $-17.17M | $-39.00M | $-2.10M | $-1.94M | $-2.05M | $-32.00M | $-18.28M | $-375.26M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 71.45% | 25.70% | 0.89% | 17.52% | 0.89% | -0.43% | 0.82% | 13.21% | 12.86% | 8.97% | 1.01% | 1.06% | 0.04% |
5 analysts predict ASMB's average Quarter EBITDA for Sep 20 to be $-3.62M, with a high of $-3.62M and a low of $-3.62M. This is -148.93% lower than Assembly Biosciences's previous annual EBITDA (Jun 20) of $7.39M.
Assembly Biosciences Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 7 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 10 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | $-60.26M | $-23.59M | $-27.20M | $-39.42M | $-3.35M | $7.27M | $-26.66M | $-27.08M | $-25.00M | $-18.50M | $-27.05M | $-16.25M | $-13.93M |
| Avg Forecast | $-17.91M | $-17.59M | $-14.80M | $-11.56M | $-11.81M | $-11.81M | $-11.62M | $-14.04M | $-12.53M | $-14.63M | $-14.16M | $-32.91M | $-44.69M | $-30.64M | $-59.47M | $-50.78M | $-2.03M | $-32.64M | $-68.22M | $-62.97M | $-76.52M | $-26.79M | $-15.39M | $-313.44M |
| High Forecast | $-16.84M | $-16.54M | $-13.91M | $-10.87M | $-11.10M | $-11.10M | $-10.93M | $-12.39M | $-10.75M | $-13.75M | $-13.31M | $-32.91M | $-44.69M | $-24.51M | $-59.47M | $-50.78M | $-2.03M | $-26.11M | $-68.22M | $-62.97M | $-76.52M | $-21.43M | $-12.31M | $-250.75M |
| Low Forecast | $-18.99M | $-18.65M | $-15.69M | $-12.25M | $-12.52M | $-12.52M | $-12.32M | $-15.69M | $-14.32M | $-15.51M | $-15.01M | $-32.91M | $-44.69M | $-36.77M | $-59.47M | $-50.78M | $-2.03M | $-39.17M | $-68.22M | $-62.97M | $-76.52M | $-32.15M | $-18.47M | $-376.13M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.83% | 0.53% | 0.89% | 0.66% | 0.07% | -3.58% | 0.82% | 0.40% | 0.40% | 0.24% | 1.01% | 1.06% | 0.04% |
Assembly Biosciences's average Quarter net income forecast for Sep 20 is $-50.78M, with a range of $-50.78M to $-50.78M. ASMB's average Quarter net income forecast represents a -798.55% decrease compared to the company's last Quarter net income of $7.27M (Jun 20).
Assembly Biosciences SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 7 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 10 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | $6.50M | $6.92M | $8.70M | $7.17M | $11.69M | $9.47M | $8.73M | $10.83M | $8.49M | $4.08M | $9.52M | $5.70M | $4.04M |
| Avg Forecast | $8.61M | $9.19M | $9.06M | $19.26M | $19.49M | $19.04M | $18.47M | $18.02M | $11.78M | $13.07M | $13.60M | $3.52M | $3.66M | $5.65M | $8.95M | $14.50M | $68.83M | $8.60M | $8.41M | $7.76M | $8.22M | $7.22M | $7.64M | $56.76K |
| High Forecast | $9.01M | $9.62M | $9.48M | $20.15M | $20.39M | $19.91M | $19.32M | $19.21M | $12.87M | $13.67M | $14.22M | $3.52M | $3.66M | $5.65M | $8.95M | $14.50M | $68.83M | $8.60M | $8.41M | $7.76M | $8.22M | $7.22M | $9.17M | $68.11K |
| Low Forecast | $8.21M | $8.77M | $8.65M | $18.37M | $18.59M | $18.16M | $17.62M | $16.82M | $10.68M | $12.47M | $12.97M | $3.52M | $3.66M | $5.65M | $8.95M | $14.50M | $68.83M | $8.60M | $8.41M | $7.76M | $8.22M | $7.22M | $6.11M | $45.40K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.85% | 1.89% | 1.54% | 0.80% | 0.81% | 0.14% | 1.01% | 1.29% | 1.09% | 0.50% | 1.32% | 0.75% | 71.19% |
Assembly Biosciences's average Quarter SG&A projection for Jun 24 is $13.60M, based on 1 Wall Street analysts, with a range of $12.97M to $14.22M. The forecast indicates a 109.05% rise compared to ASMB last annual SG&A of $6.50M (Dec 21).
Assembly Biosciences EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 7 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 10 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | $-1.32 | $-0.55 | $-0.69 | $-0.99 | $-0.09 | $0.21 | $-0.76 | $-0.77 | $-0.96 | $-0.72 | $-1.05 | $-0.80 | $-0.81 |
| Avg Forecast | $-2.82 | $-2.77 | $-2.33 | $-1.82 | $-1.86 | $-1.86 | $-1.83 | $-2.21 | $-1.97 | $-2.30 | $-2.23 | $-5.83 | $-7.92 | $-9.26 | $-10.54 | $-9.00 | $-0.36 | $-11.73 | $-12.09 | $-11.16 | $-13.56 | $-12.76 | $-0.72 | $-0.68 |
| High Forecast | $-2.65 | $-2.60 | $-2.19 | $-1.71 | $-1.75 | $-1.75 | $-1.72 | $-1.95 | $-1.69 | $-2.17 | $-2.10 | $-5.83 | $-7.92 | $-9.26 | $-10.54 | $-9.00 | $-0.36 | $-11.73 | $-12.09 | $-11.16 | $-13.56 | $-12.76 | $-0.58 | $-0.54 |
| Low Forecast | $-2.99 | $-2.94 | $-2.47 | $-1.93 | $-1.97 | $-1.97 | $-1.94 | $-2.47 | $-2.25 | $-2.44 | $-2.36 | $-5.83 | $-7.92 | $-9.26 | $-10.54 | $-9.00 | $-0.36 | $-11.73 | $-12.09 | $-11.16 | $-13.56 | $-12.76 | $-0.86 | $-0.81 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.23% | 0.07% | 0.07% | 0.09% | 0.01% | -0.58% | 0.06% | 0.06% | 0.09% | 0.05% | 0.08% | 1.11% | 1.19% |
According to 5 Wall Street analysts, Assembly Biosciences's projected average Quarter EPS for Sep 20 is $-9.00, with a low estimate of $-9.00 and a high estimate of $-9.00. This represents a -4385.71% decrease compared to ASMB previous annual EPS of $0.21 (Jun 20).
Assembly Biosciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SPRO | Spero Therapeutics | $1.04 | $10.00 | 861.54% | Buy |
| TIL | Instil Bio | $21.69 | $150.00 | 591.56% | Hold |
| NXTC | NextCure | $0.90 | $3.00 | 233.33% | Buy |
| CTMX | CytomX Therapeutics | $1.13 | $3.47 | 207.08% | Buy |
| NUVB | Nuvation Bio | $2.81 | $7.00 | 149.11% | Buy |
| ASMB | Assembly Biosciences | $14.28 | $35.50 | 148.60% | Buy |
| ACHL | Achilles Therapeutics | $0.97 | $2.00 | 106.19% | Buy |